REGENX Biosciences, LLC and Voyager Therapeutics have entered into a license agreement for the use of REGENX’s NAV vectors for the development and commercialization of gene therapies to treat Amyotrophic Lateral Sclerosis (ALS), Friedreich’s ataxia (FA) and Huntington’s disease (HD).
 
Voyager has a non-exclusive worldwide license, as well as sublicensing rights, to the NAV vectors for the treatment of ALS, FA and HD. REGENX will receive an undisclosed upfront payment, ongoing fees, milestones, and royalties on sales of products incorporating NAV vectors. REGENX will also receive certain sublicensing revenues.
 
“This license agreement serves as further validation of our proprietary NAV vector technology platform, and is an important step toward the successful development of NAV-based gene delivery treatments for patients afflicted with the serious and debilitating rare diseases to which Voyager is committed,” said Ken Mills, president and chief executive officer of REGENX. “As the leader in next-generation AAV gene therapy, REGENX is pleased to be collaborating with Voyager, which is well-positioned to develop innovative treatments through the application of our NAV technology.”
 
Mark Levin, interim chief executive officer of Voyager, said, “Voyager is the leading
AAV gene therapy company focused on developing life-changing treatments for patients with devastating CNS disorders. We are committed to advancing the AAV gene therapy field via broad-based investment in a number of key technological areas. In addition to providing a valuable addition to Voyager’s intellectual property portfolio, the rights to use REGENX’s NAV vectors will position us to rapidly advance the development of breakthrough CNS gene therapies.”